Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):458–467. doi: 10.1038/sj.bjc.6690379

Alteration of p16 and p15 genes in human uterine tumours

R Nakashima 1, M Fujita 1, T Enomoto 1, T Haba 2, K Yoshino 1, H Wada 1, H Kurachi 1, M Sasaki 2, K Wakasa 2, M Inoue 3, G Buzard 3, Y Murata 1
PMCID: PMC2362344  PMID: 10408854

Abstract

The roles of the p16 and p15 inhibitor of cyclin-dependent kinase tumour suppressor genes were examined in human uterine cervical and endometrial cancers. p16 mRNA, examined by reverse transcription polymerase chain reaction (RT-PCR), was significantly reduced in five of 19 (26%) cervical and four of 25 (16%) endometrial tumours. Reduced expression of p16 protein, detected by immunohistochemistry, occurred even more frequently, in nine of 33 (27%) cervical and seven of 37 (19%) endometrial tumours. Hypermethylation of a site within the 5′-CpG island of the p16 gene was detected in only one of 32 (3%) cervical tumours and none of 26 endometrial tumours. Homozygous p16 gene deletion, evaluated by differential PCR analysis, was found in four of 40 (10%) cervical tumours and one of 38 (3%) endometrial tumours. Homozygous deletion of p15 was found in three of 40 (8%) cervical tumours and one of 38 (3%) endometrial tumours. PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). Three were mis-sense mutations, one in codon 74 (CTG→ATG) and one in codon 129 (ACC→ATC), both in cervical carcinomas, and the other was in codon 127 (GGG→GAG) in an endometrial carcinoma. There was one non-sense mutation, in codon 50 (CGA→TGA), in an endometrial carcinoma. The remaining two were silent somatic cell mutations, both in cervical carcinomas, resulting in no amino acid change. These observations suggest that inactivation of the p16 gene, either by homologous deletion, mutation or loss of expression, occurs in a subset of uterine tumours. © 1999 Cancer Research Campaign

Keywords: p16, p15, cervical carcinoma, endometrial carcinoma, methylation, immunohistochemistry

Full Text

The Full Text of this article is available as a PDF (346.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Enomoto T., Fujita M., Inoue M., Rice J. M., Nakajima R., Tanizawa O., Nomura T. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res. 1993 Apr 15;53(8):1883–1888. [PubMed] [Google Scholar]
  2. Enomoto T., Weghorst C. M., Inoue M., Tanizawa O., Rice J. M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol. 1991 Oct;139(4):777–785. [PMC free article] [PubMed] [Google Scholar]
  3. Foulkes W. D., Flanders T. Y., Pollock P. M., Hayward N. K. The CDKN2A (p16) gene and human cancer. Mol Med. 1997 Jan;3(1):5–20. [PMC free article] [PubMed] [Google Scholar]
  4. Fujita M., Inoue M., Tanizawa O., Iwamoto S., Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res. 1992 Oct 1;52(19):5323–5328. [PubMed] [Google Scholar]
  5. Fuqua S. A., Falette N. F., McGuire W. L. Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. J Natl Cancer Inst. 1990 May 16;82(10):858–861. doi: 10.1093/jnci/82.10.858. [DOI] [PubMed] [Google Scholar]
  6. Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., Van Tornout J. M., Jones P. A. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995 Oct 15;55(20):4531–4535. [PubMed] [Google Scholar]
  7. Guan K. L., Jenkins C. W., Li Y., Nichols M. A., Wu X., O'Keefe C. L., Matera A. G., Xiong Y. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 1994 Dec 15;8(24):2939–2952. doi: 10.1101/gad.8.24.2939. [DOI] [PubMed] [Google Scholar]
  8. Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994 Sep 15;371(6494):257–261. doi: 10.1038/371257a0. [DOI] [PubMed] [Google Scholar]
  9. Hatta Y., Hirama T., Takeuchi S., Lee E., Pham E., Miller C. W., Strohmeyer T., Wilczynski S. P., Melmed S., Koeffler H. P. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J Urol. 1995 Nov;154(5):1954–1957. [PubMed] [Google Scholar]
  10. Hengstschläger M., Hengstschläger-Ottnad E., Pusch O., Wawra E. The role of p16 in the E2F-dependent thymidine kinase regulation. Oncogene. 1996 Apr 18;12(8):1635–1643. [PubMed] [Google Scholar]
  11. Herman J. G., Jen J., Merlo A., Baylin S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996 Feb 15;56(4):722–727. [PubMed] [Google Scholar]
  12. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995 Oct 15;55(20):4525–4530. [PubMed] [Google Scholar]
  13. Hirama T., Miller C. W., Wilczynski S. P., Koeffler H. P. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines. Mod Pathol. 1996 Jan;9(1):26–31. [PubMed] [Google Scholar]
  14. Jen J., Harper J. W., Bigner S. H., Bigner D. D., Papadopoulos N., Markowitz S., Willson J. K., Kinzler K. W., Vogelstein B. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 1994 Dec 15;54(24):6353–6358. [PubMed] [Google Scholar]
  15. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  16. Kelley M. J., Otterson G. A., Kaye F. J., Popescu N. C., Johnson B. E., Dipaolo J. A. CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer. 1995 Oct 9;63(2):226–230. doi: 10.1002/ijc.2910630214. [DOI] [PubMed] [Google Scholar]
  17. Kim J. W., Namkoong S. E., Ryu S. W., Kim H. S., Shin J. W., Lee J. M., Kim D. H., Kim I. K. Absence of p15INK4B and p16INK4A gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection. Gynecol Oncol. 1998 Jul;70(1):75–79. doi: 10.1006/gyno.1998.5041. [DOI] [PubMed] [Google Scholar]
  18. Lo K. W., Cheung S. T., Leung S. F., van Hasselt A., Tsang Y. S., Mak K. F., Chung Y. F., Woo J. K., Lee J. C., Huang D. P. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 1996 Jun 15;56(12):2721–2725. [PubMed] [Google Scholar]
  19. Lu X., Toki T., Konishi I., Nikaido T., Fujii S. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer. 1998 Jun 15;82(12):2409–2417. [PubMed] [Google Scholar]
  20. Lukas J., Petersen B. O., Holm K., Bartek J., Helin K. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol Cell Biol. 1996 Mar;16(3):1047–1057. doi: 10.1128/mcb.16.3.1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Marchetti A., Buttitta F., Pellegrini S., Bertacca G., Chella A., Carnicelli V., Tognoni V., Filardo A., Angeletti C. A., Bevilacqua G. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. J Pathol. 1997 Feb;181(2):178–182. doi: 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  22. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995 Jul;1(7):686–692. doi: 10.1038/nm0795-686. [DOI] [PubMed] [Google Scholar]
  23. Munirajan A. K., Kannan K., Bhuvarahamurthy V., Ishida I., Fujinaga K., Tsuchida N., Shanmugam G. The status of human papillomavirus and tumor suppressor genes p53 and p16 in carcinomas of uterine cervix from India. Gynecol Oncol. 1998 Jun;69(3):205–209. doi: 10.1006/gyno.1998.4991. [DOI] [PubMed] [Google Scholar]
  24. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. doi: 10.1038/368753a0. [DOI] [PubMed] [Google Scholar]
  25. Owen D., Kühn L. C. Noncoding 3' sequences of the transferrin receptor gene are required for mRNA regulation by iron. EMBO J. 1987 May;6(5):1287–1293. doi: 10.1002/j.1460-2075.1987.tb02366.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Parker M. F., Arroyo G. F., Geradts J., Sabichi A. L., Park R. C., Taylor R. R., Birrer M. J. Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol. 1997 Feb;64(2):242–251. doi: 10.1006/gyno.1996.4580. [DOI] [PubMed] [Google Scholar]
  27. Peiffer S. L., Bartsch D., Whelan A. J., Mutch D. G., Herzog T. J., Goodfellow P. J. Low frequency of CDKN2 mutation in endometrial carcinomas. Mol Carcinog. 1995 Aug;13(4):210–212. doi: 10.1002/mc.2940130403. [DOI] [PubMed] [Google Scholar]
  28. Pollock P. M., Pearson J. V., Hayward N. K. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer. 1996 Feb;15(2):77–88. doi: 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  29. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
  30. Sheffield V. C., Beck J. S., Kwitek A. E., Sandstrom D. W., Stone E. M. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics. 1993 May;16(2):325–332. doi: 10.1006/geno.1993.1193. [DOI] [PubMed] [Google Scholar]
  31. Shiozawa T., Nikaido T., Shimizu M., Zhai Y., Fujii S. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer. 1997 Dec 15;80(12):2250–2256. doi: 10.1002/(sici)1097-0142(19971215)80:12<2250::aid-cncr5>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  32. Stone S., Jiang P., Dayananth P., Tavtigian S. V., Katcher H., Parry D., Peters G., Kamb A. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res. 1995 Jul 15;55(14):2988–2994. [PubMed] [Google Scholar]
  33. Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T., Takahashi T., Takahashi T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res. 1995 Feb 1;55(3):514–517. [PubMed] [Google Scholar]
  34. Wong Y. F., Chung T. K., Cheung T. H., Nobori T., Yim S. F., Lai K. W., Phil M., Yu A. L., Diccianni M. B., Li T. Z. p16INK4 and p15INK4B alterations in primary gynecologic malignancy. Gynecol Oncol. 1997 May;65(2):319–324. doi: 10.1006/gyno.1997.4669. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES